Early onset of treatment effects with oral risperidone

Raedler, Thomas J.; Schreiner, Andreas; Naber, Dieter; Wiedemann, Klaus
January 2007
BMC Psychiatry;2007, Vol. 7, p4
Academic Journal
Background: The dogma of a delayed onset of antipsychotic treatment effects has been maintained over the past decades. However, recent studies have challenged this concept. We therefore performed an analysis of the onset of antipsychotic treatment effects in a sample of acutely decompensated patients with schizophrenia. Methods: In this observational study, 48 inpatients with acutely decompensated schizophrenia were offered antipsychotic treatment with oral risperidone. PANSS-ratings were obtained on day 0, day 1, day 3, day 7 and day 14. Results: Significant effects of treatment were already present on day 1 and continued throughout the study. The PANSS positive subscore and the PANSS total score improved significantly more than the PANSS negative subscore. Conclusion: Our results are consistent with the growing number of studies suggesting an early onset of antipsychotic treatment effects. However, non-pharmacological effects of treatment also need to be taken into consideration.


Related Articles

  • Establishing cost-effectiveness of atypical neuroleptics. Robert, Glenn; Kennedy, Peter; Robert, G; Kennedy, P // British Journal of Psychiatry;Aug97, Vol. 171, p103 

    The article discusses a small-sample "before and after" cohort study of clozapine therapy which can provide a useful approach to handling costs when comparing treatments. The study showed that it is not difficult to obtain costing data. Evidence from 14 short-term double-blind comparisons showed...

  • No Influence of DTNBP1 Polymorphisms on the Response to Aripiprazole. Chi-Un Pae; Chiesa, Alberto; Mandelli, Laura; Serretti, Alessandro // Neuropsychobiology;2010, Vol. 62 Issue 4, p245 

    Aims: The aim of the present study was to investigate pos- sible influences of a panel of markers in the dysbindin gene DTNBP1 (rs3213207, rs1011313, rs2005976, rs760761 and rs2619522) on the clinical outcome and side effects associated to the treatment with aripiprazole in schizophrenic...

  • The efficacy of electroconvulsive therapy in the treatment of schizophrenia. A comparative study. Abraham, K.R.; Kulhara, P. // British Journal of Psychiatry;Aug87, Vol. 151, p152 

    The efficacy of ECT was investigated in a double-blind trial. Twenty-two patients with schizophrenia received trifluoperazine and were randomly allocated to receive eight real or eight simulated ECTs. In the first eight weeks, the group receiving real ECTs showed significantly more improvement...

  • New class of antipsychotic drugs for schizophrenia. Breier, Alan // Cortlandt Forum;07/25/97, Vol. 10 Issue 7, p23 

    Describes antipsychotic drugs for the treatment of schizophrenia in the United States. Clozapine; Risperidone; Olanzapine; Sertindole; Comparison to haloperidol-like drugs.

  • The promise of new drugs for schizophrenia treatment. Tamminga, C. A.; Tamminga, Ca // Canadian Journal of Psychiatry;Apr1997, Vol. 42 Issue 3, p265 

    Objective: To present aspects of preclinical and clinical pharmacology of new antipsychotic drugs and to emphasize those preclinical drug characteristics which might predict desirable clinical actions.Method: Review of the relevant literature and publicly presented...

  • Effects of Risperidone on Learning and Memory in Naive and MK-801-Treated Rats. Celikyurt, Ipek Komsuoglu; Akar, Furuzan Yildiz; Ulak, Guner; Mutlu, Oguz; Erden, Faruk // Pharmacology;2011, Vol. 87 Issue 3/4, p187 

    Background/Aims: The aim of this study was to investigate the effects of an atypical antipsychotic risperidone (RIS; 0.06, 0.125 or 0.25 mg/kg, intraperitoneal, i.p.) on learning and memory processes, both in naive and MK-801-treated (0.15 mg/kg, i.p.) rats. Methods: Modified elevated plus maze...

  • The lifetime outcome and involuntary movements of schizophrenia never treated with neuroleptic drugs. Four rare cases in Ireland. Waddington, John L.; Youssef, Hanafy A.; Waddington, J L; Youssef, H A // British Journal of Psychiatry;Jan90, Vol. 156, p106 

    Four elderly schizophrenic patients who had never been treated with neuroleptics, and a fifth patient who had received only the briefest exposure to such drugs, had retained their distinct clinical characteristics. Involuntary orofacial movements and cognitive dysfunction were found more...

  • Psychiatrists' Attitudes toward Metabolic Adverse Events in Patients with Schizophrenia. Sugawara, Norio; Yasui-Furukori, Norio; Yamazaki, Manabu; Shimoda, Kazutaka; Mori, Takao; Sugai, Takuro; Suzuki, Yutaro; Someya, Toshiyuki // PLoS ONE;Jan2014, Vol. 9 Issue 1, p1 

    Background: There is growing concern about the metabolic abnormalities in patients with schizophrenia. Aims: The aim of this study was to assess the attitudes of psychiatrists toward metabolic adverse events in patients with schizophrenia. Method: A brief questionnaire was constructed to cover...

  • In Vivo Pharmacological Evaluations of Novel Olanzapine Analogues in Rats: A Potential New Avenue for the Treatment of Schizophrenia. Jafari, Somayeh; Huang, Xu-Feng; Andrews, Jessica L.; Fernandez-Enright, Francesca // PLoS ONE;Dec2013, Vol. 8 Issue 12, p1 

    Olanzapine (Olz) is one of the most effective antipsychotic drugs commonly used for treating schizophrenia. Unfortunately, Olz administration is associated with severe weight gain and metabolic disturbances. Both patients and clinicians are highly interested in the development of new...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics